No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[Failed to load article at https://www.morningstar.com/news/accesswire/1120988msn/cosmos-health-is-building-a-platform-and-tariffs-are-accelerating-the-strategy]


[TITLE]India sets 2026 health agenda: Drug quality, innovation, TB and obesity take centre stage:
[TEXT]
Experts and industry stakeholders emphasized that the immediate test of India's commitment is the implementation of revised good manufacturing practices (GMP). These norms, aligned with World Health Organization standards, become compulsory for small pharmaceutical companies—those with a turnover of less than ₹250 crore—starting 1 January 2026. Companies that do not comply could be shut down. (Lobbying is on to extend this deadline but a decision has not been taken by the government.)
[Source link]: https://www.livemint.com/industry/india-health-2026-agenda-quality-drugs-innovation-obesity-tb-weight-loss-r-d-gmp-ai-pollution-digital-healthcare-11765903909679.html


[TITLE]Health Insurance Management System Market Size, Brand Growth, Trends & Outlook 2026-2033:
[TEXT]
Health Insurance Management System Market Global Outlook, Country Deep-Dives & Strategic Opportunities (2024-2033) Market size (2024): USD 3.5 billion · Forecast (2033): 9.17 Billion USD · CAGR: 12.8%

Current Market Trends

The global health insurance management system market is experiencing rapid evolution driven by technological advancements and shifting consumer expectations. Increasing adoption of cloud-based solutions allows insurers to enhance scalability and reduce infrastructure costs, leading to more flexible service delivery. The integration of telehealth services within management platforms is gaining traction, providing seamless virtual consultations and improving patient engagement. Regulatory compliance remains a critical focus, prompting the adoption of systems that facilitate real-time reporting and data security. Additionally, there is a rising trend toward personalized health plans enabled by data analytics, which cater to individual health needs and preferences. The market is also witnessing a surge in mergers and acquisitions, aimed at expanding technological capabilities and market reach. Furthermore, mobile health management apps are becoming more prevalent, offering users easy access to policy information, claims processing, and wellness tracking. Overall, these trends reflect a shift toward more efficient, user-centric, and technologically integrated health insurance management solutions.

Get the full PDF sample copy of the report: (Includes full table of contents, list of tables and figures, and graphs):- https://www.marketsizeandtrends.com/download-sample/1000207/?utm_source=Pulse-BB6&utm_medium=204&utm_country=Global

How AI is Transforming the Industry

Artificial Intelligence (AI) is revolutionizing the health insurance management landscape by automating complex processes and enhancing decision-making accuracy. AI-powered chatbots and virtual assistants are streamlining customer service, providing instant responses to inquiries, and guiding users through policy options and claims procedures. Machine learning algorithms analyze vast amounts of health data to identify risk patterns, enabling insurers to develop more accurate underwriting models and personalized premium calculations. AI-driven predictive analytics assist in early detection of potential health issues, promoting proactive care management and reducing overall costs. Fraud detection systems leverage AI to identify suspicious claims and prevent fraudulent activities, safeguarding insurer assets. Additionally, AI enhances claims processing efficiency by automating document verification and validation, reducing processing time significantly. The integration of AI in health management systems also facilitates real-time monitoring of patient health data, enabling more tailored interventions. Overall, AI's capabilities are leading to smarter, faster, and more personalized health insurance management solutions, ultimately improving customer satisfaction and operational efficiency.

Key Growth Drivers

Technological Advancements: The rapid development of cloud computing, AI, and data analytics is enabling more sophisticated and scalable management systems.

Rising Healthcare Costs: Increasing healthcare expenses drive demand for efficient management solutions that optimize resource allocation and reduce administrative costs.

Regulatory Compliance: Evolving regulations necessitate advanced systems capable of real-time reporting, data security, and compliance management.

Consumer Demand for Personalization: Growing preference for tailored health plans and digital engagement tools fuels innovation in management platforms.

Digital Transformation Initiatives: Insurers are investing heavily in digital infrastructure to improve customer experience and operational agility.

Global Health Challenges: The COVID-19 pandemic underscored the need for resilient and adaptable health management systems capable of handling crises.

Consumer Insights

Preference for Digital Access: Consumers favor mobile apps and online portals for easy policy management, claims filing, and health tracking.

Demand for Transparency: Clear, real-time information
[Source link]: https://www.linkedin.com/pulse/health-insurance-management-system-market-size-yrqge


[TITLE]United States Health Maintenance Organization (hmo) Insurance Market Size 2026 | Brands, Opportunity & Risks 2033:
[TEXT]
United States Health Maintenance Organization (hmo) Insurance
[Source link]: https://www.linkedin.com/pulse/united-states-health-maintenance-organization-hmo-ysxcc


===== Company info for companies mentioned in news =====

Company name: cosmos health
symbol: COSM
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1766884743
name: cosmos health
------------------------------------------------------------------

Company name: health insurance management system
name: health insurance management system
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=health+insurance+management+system&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: teva pharmaceutical
symbol: TEVA
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1766884744
name: teva pharmaceutical
------------------------------------------------------------------

Company name: united states health maintenance organization
name: united states health maintenance organization
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=united+states+health+maintenance+organization&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction:
[TEXT]
RAMAT GAN, Israel, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced that the Brazilian Patent Office (INPI) has granted Patent No. BR112015002697-4, entitled “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.”

The granted patent provides intellectual-property protection in Brazil for the use of Can-Fite’s proprietary A3AR agonists in the treatment of sexual dysfunction, further strengthening the Company’s global patent portfolio. Brazil represents one of the largest pharmaceutical markets in Latin America, with a growing demand for innovative therapies addressing sexual health conditions.

Sexual dysfunction is associated with vascular, inflammatory, and metabolic pathways. Preclinical and clinical data generated by Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms involved in erectile and sexual function, supporting the therapeutic rationale underlying the patent.

“The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market,” said Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma. “This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America.”

Can-Fite continues to advance its A3AR agonist platform across multiple indications, including oncology, inflammatory diseases, and additional non-oncologic conditions, while actively evaluating strategic opportunities to maximize the value of its patent estate.
[Source link]: https://www.globenewswire.com/news-release/2025/12/26/3210520/0/en/Can-Fite-Granted-Brazilian-Patent-for-Treatment-of-Sexual-Dysfunction.html


[TITLE]MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings:
[TEXT]
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine

CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that independent directors including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D. purchased common stock and warrants in the recent private placement offering which closed on December 22, 2025.

Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception in 2018, and Ms. Adelina Louie is a top investor in MAIA. Gross proceeds from the offering totaled approximately $1.51 million.

To date, directors and officers hold 5,019,857 shares or 13.43% of MAIA.

“Ongoing support from our directors reflects their strong conviction in the commercial potential of ateganosine, our first-in-class anticancer treatment for advanced non-small cell lung cancer (NSCLC),” said Vlad Vitoc, M.D., founder and CEO of MAIA. “Consistent insider participation in our 2025 financings strengthens our ability to execute as we advance our pivotal Phase 3 international trial launched this month with first patient dosing.”

Dr. Smith commented, “Our continued support reflects our strong confidence in the scientific differentiation and commercial promise of ateganosine. The initiation of the pivotal Phase 3 trial marks an important value-creation milestone for MAIA.”

Ms. Adelina Louie stated, “I believe MAIA has reached a pivotal stage in advancing life-changing therapies to broad populations of patients with cancer, and I am proud continue to support the Company in my capacity as both an investor and a member of the Board.”

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. Statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.
[Source link]: https://www.globenewswire.com/news-release/2025/12/24/3210313/0/en/MAIA-Biotechnology-Board-Members-Continue-to-Participate-in-Private-Placement-Financings.html


[TITLE]Cell Therapy Technologies Market is expected to generate a revenue of USD 8.4 Billion by 2032, Globally, at 4.4% CAGR: Verified Market Research®:
[TEXT]
Lewes, Delaware, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The Global Cell Therapy Technologies Market Size projected to grow at a CAGR of 4.4% from 2026 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 4.07 Billion in 2024 and expected to reach USD 8.4 Billion by the end of the forecast period.

For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Cell Therapy Technologies Market.

Browse in-depth TOC

202 - Pages

126 – Tables

37 – Figures

Global Cell Therapy Technologies Market Overview

Market Driver:

Rising Demand for Personalized and Regenerative Medicine:

The growing shift toward personalized and regenerative medicine remains a primary growth driver for the Cell Therapy Technologies Market. Healthcare systems worldwide are moving away from one-size-fits-all treatments and adopting patient-specific therapeutic solutions. Cell-based therapies enable precise targeting of disease pathways, improving clinical outcomes for cancer, autoimmune disorders, and rare genetic conditions. This evolution directly increases demand for advanced cell processing, expansion, storage, and delivery technologies.

Key growth-enabling factors include:

Increasing clinical adoption of autologous and allogeneic cell therapies

Rising success rates of regenerative treatments across multiple indications

Growing demand for precision cell handling and cryopreservation systems

Expansion of personalized medicine programs by hospitals and biopharma firms

As investment in regenerative medicine continues to rise, companies actively seek data-driven insights to optimize technology procurement and commercialization strategies. This trend strengthens demand for decision-grade Cell Therapy Technologies Market reports supporting strategic purchases and long-term planning.

Strong Growth in Oncology and Immunotherapy Research:

The rising global cancer burden significantly accelerates adoption of cell therapy technologies, particularly within oncology and immunotherapy applications. CAR-T cell therapy, T-cell receptor therapies, and NK cell therapies are transforming cancer treatment protocols. Biopharmaceutical companies continue to expand oncology pipelines, driving demand for reliable cell collection, genetic modification, and quality control technologies.

Key market-enabling dynamics include:

Rapid growth in cancer incidence driving innovation-focused investments

Expansion of immunotherapy clinical trials across multiple regions

Increased funding from governments and private investors

Rising demand for scalable and compliant manufacturing platforms

As oncology-focused cell therapies move toward commercialization, technology providers experience increased procurement demand. Market research reports become critical tools for stakeholders evaluating competitive positioning, pricing benchmarks, and investment opportunities within the high-growth oncology segment.

Advancements in Cell Processing, Automation, and Manufacturing Technologies:

Technological innovation in automation and closed-system manufacturing platforms continues to drive the Cell Therapy Technologies Market forward. Companies increasingly deploy automated cell processing solutions to enhance reproducibility, reduce contamination risks, and lower operational dependency on skilled labor. These advancements improve scalability and accelerate time-to-market for commercial therapies.

Technology-driven growth factors include:

Adoption of closed and automated cell processing systems

Integration of digital monitoring and quality control technologies

Development of scalable bioreactors and cell expansion platforms

Growing preference for standardized manufacturing workflows

Automation improves cost efficiency and regulatory compliance, making cell therapies more commercially viable. As competition intensifies, stakeholders rely on validated market intelligence to compare technologies, assess vendor capabilities, and make confident purchasing decisions.

Market Restraints:

High Manufacturing Costs and Complex Production Processes:

High production costs remain a significant restraint impacting the growth of the Cell Therapy Technologies Market. Manufacturing cell therapies requires specialized infrastructure, cleanroom facilities, and highly trained personnel. Autologous therapies, in particular, lack economies of scale, increasing per-patient treatment costs and limiting affordability.

Key cost-related challenges include:

Capital-intensive manufacturing and processing infrastructure

High labor and quality assurance expenses

Limited scalability of patient-specific therapies

Expensive raw materials and consumables

These factors create financial barriers for emerging biotech firms and healthcare providers. As a result, organizations increasingly invest in detailed market research reports to analyze cost structures, optimize procurement strategies, and reduce investment risk before entering or expanding within the market.

Stringent Regulatory Requirements and Approval Challenges:

Regulatory complexity significantly restrains commercialization efforts in the Cell Therapy Technologies Market. Cell-based therapies must meet strict safety, efficacy, and manufacturing consistency standards. Regulatory frameworks vary across regions, creating additional compliance challenges and delaying product approvals.

Key regulatory barriers include:

Lengthy clinical trial and approval timelines

Variability in regional regulatory requirements

High compliance and documentation costs

Limited regulatory clarity for novel cell therapy platforms

These challenges increase time-to-market and financial risk. For stakeholders, purchasing a comprehensive market research report provides critical insights into regulatory trends, approval pathways, and region-specific compliance strategies, enabling informed market entry and expansion decisions.

Scalability, Supply Chain, and Workforce Limitations:

Scaling cell therapy technologies from clinical development to commercial production remains a persistent challenge. Maintaining cell viability during storage and transportation requires advanced cold-chain logistics and reliable supply chain infrastructure. Additionally, the shortage of skilled professionals limits rapid capacity expansion.

Operational constraints include:

Cold-chain logistics complexity and high transportation costs

Limited availability of skilled cell therapy specialists

Inconsistent supply of high-quality raw materials

Challenges in maintaining cell integrity at scale

These limitations restrict global market expansion and slow commercialization timelines. As competition increases, companies rely on data-backed market intelligence to identify scalable solutions, optimize supply chains, and align long-term growth strategies with market realities.

Download a free sample to access exclusive Insights, Data Charts, And Forecasts From The Cell Therapy Technologies Market Sample Report.

Geographical Dominance: North America dominates the Cell Therapy Technologies Market due to strong biopharmaceutical infrastructure, advanced clinical research capabilities, and high investment in regenerative medicine and oncology. The United States leads regional growth, supported by favorable reimbursement frameworks, robust FDA regulatory pathways, and the presence of major cell therapy technology providers. Europe follows closely, driven by rising adoption of advanced therapies in Germany, the UK, and France, along with strong academic–industry collaborations. The Asia Pacific region is emerging as a high-growth market, led by China, Japan, and South Korea, where increasing government funding, expanding biotech manufacturing hubs, and cost-efficient clinical trials accelerate adoption. These regional dynamics make detailed market research reports essential for identifying expansion opportunities and guiding data-driven investment decisions.

Key Players

The “Global Cell Therapy Technologies Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Beckman Coulter, Inc., Becton, Dickinson and Company, GE Healthcare, Lonza, Merck KGaA, MiltenyiBiotec, STEMCELL Technologies, Inc., Terumo BCT, Inc., Thermo Fisher Scientific, Inc., Sartorius AG, Terumo BCT, Fresenius Medical Care AG & Co., KGaA, Avantor, Inc.

Cell Therapy Technologies Market Segment Analysis

Based on the research, Verified Market Research has segmented the global market into Product Type, Process, Application, and Geography.

Cell Therapy Technologies Market, by Product Type: Media Sera & Reagents Vessels Cell Therapy Equipment Systems & Software

Cell Therapy Technologies Market, by Process: Cell Processing Cell Preservation Cell Distribution Cell Handling Process Monitoring & Quality Control

Cell Therapy Technologies Market, by Application: Cancer Cardiovascular Disease Orthopedic Disorders Autoimmune Diseases

Cell Therapy Technologies Market, by Geography North America U.S Canada Mexico Europe Germany France U.K Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific ROW Middle East & Africa Latin America

Strategic Insight:

The Cell Therapy Technologies Market presents strong growth potential driven by rising demand for personalized medicine, rapid expansion of oncology and immunotherapy pipelines, and continuous advancements in automated cell processing technologies. However, high manufacturing costs, regulatory complexity, and scalability challenges require well-planned market entry strategies. North America remains the primary revenue-generating region, while Asia Pacific offers high-growth opportunities through cost-efficient manufacturing and supportive government initiatives. Companies seeking to enter or expand in this market must focus on technology differentiation, regulatory readiness, and regional expansion planning. Purchasing a comprehensive Cell Therapy Technologies Market report enables stakeholders to identify high-return opportunities, mitigate risks, and execute data-driven investment and commercialization strategies.

To gain complete access with Corporate Or Enterprise Licensing, Visit The Cell Therapy Technologies Market.

Key Highlights of the Report:

Market Size & Forecast : In-depth analysis of current value and future projections Segment Analysis : Breaks down the market by Product Type, Process, and Application for focused strategy development. Regional Insights : Comprehensive coverage of North America, Europe, Asia-Pacific, and more Competitive Landscape : Profiles key players, their strategic initiatives, and innovation-driven growth approaches. Growth Drivers & Challenges : Analyzes the forces accelerating growth and the restraints hindering large-scale adoption. Challenges and Risk Assessment : Evaluates ethical debates, off-target effects, and regulatory complexities.
[Source link]: https://www.globenewswire.com/news-release/2025/12/23/3210008/0/en/Cell-Therapy-Technologies-Market-is-expected-to-generate-a-revenue-of-USD-8-4-Billion-by-2032-Globally-at-4-4-CAGR-Verified-Market-Research.html


[TITLE]Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests:
[TEXT]
- TrinScreen HIV order signals renewed strength in global HIV testing market

- Company also reports a key milestone of Adjusted EBITDA1positive operations in Q3 2025 and expects to achieve strong additional profitability growth in Q1 and Q2 2026 through continued strong execution on its Comprehensive Transformation Plan

DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received an order for 9 million units of its flagship HIV screening product, TrinScreen HIV. This significant order marks a pivotal moment in the recovery and strengthening of the global health market for HIV testing, following disruptions earlier this year due to changes affecting international aid funding structures. In addition, the Company provided a trading update for its most recent financial quarters.

TrinScreen HIV Order

The order reflects a renewed commitment from global health organizations to support HIV screening efforts, particularly in regions most affected by the disease. Trinity Biotech’s TrinScreen HIV test is a WHO-prequalified, rapid diagnostic test designed for high-volume screening programs, offering reliable results and ease of use in diverse clinical settings.

Trinity Biotech will produce the tests through its recently WHO-approved outsourced manufacturing process, which allows for efficient and cost-effective scalability. The company anticipates fulfilling the order during the fourth quarter of 2025 and the first quarter of 2026, as it fine-tunes its manufacturing and supply chain to accommodate this significant rise in demand.

This order is expected to positively impact Trinity Biotech’s revenue and profitability outlook and underscores the Company’s strategic positioning in the global infectious disease diagnostics market.

Trading Update

Revenues for Q3 2025 increased by 32% to $14.3m compared to $10.8m in Q2 2025, primarily due to: A strong increase of $2.1m in rapid HIV test sales to $3.6m in Q3 2025, driven by renewed UniGold™ HIV rapid test demand and the resumption of TrinScreen HIV sales under the new manufacturing model; and A significant rise in haemoglobin product sales, rising to $5.7m compared to $4.0m in Q2 2025.

Gross profit for Q3 2025 was $6.5m compared to $4.6m in Q2 2025 driven by higher sales and an increase in gross margin from 42.6% to 45.2% supported by changes to the Company’s operating structure under its Comprehensive Transformation Plan.

Adjusted EBITDA¹ of $0.5 million for Q3 2025 compared to negative $2.1m for Q2 2025.

The Company has issued full presentations of its Q2 2025 and Q3 2025 results which can be viewed on the Company’s website www.trinitybiotech.com/investor-relations/financial-reports .

Trading Outlook

The Company continues to make substantial progress in its Comprehensive Transformation Plan, having recently secured several critical regulatory approvals, including WHO authorization for outsourcing and offshoring the production of its Uni-Gold™ HIV rapid test.

The receipt of these regulatory approvals allows the Company to proceed with the final core components of its Comprehensive Transformation Plan. These initiatives will be prioritised during the fourth quarter of 2025 and the first quarter of 2026, with the objective of realising additional efficiencies and further enhancing EBITDA performance.

Consequently, the Company expects an increase in Adjusted EBITDA1 throughout the first and second quarters of 2026 as it achieves these important operational restructuring milestones within its Comprehensive Transformation Plan.

Pipeline Developments

The Company remains committed to pursuing immediate growth opportunities that are both profitable and supported by its streamlined, more adaptable operating base. This includes ongoing expansion into international markets with its latest product offerings: An enhanced HbA1c testing solution for diabetes care; Extending the availability of its TrinScreen HIV tests to new countries.

The Company is also advancing the commercialisation of its key strategic growth projects currently in development, including: Its next-generation continuous glucose monitor, CGM+; EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease; and PrePsia™, an innovative early pregnancy screening test designed to assess the risk of preeclampsia—a potentially life-threatening condition for both mother and baby.

John Gillard, CEO of Trinity Biotech, commented:

“We are delighted to have received this TrinScreen order. It represents a strong endorsement of our product’s quality and the trust global health partners place in Trinity Biotech.

Our operating and financial improvement in Q3 2025 was encouraging, in particular the achievement of positive Adjusted EBITDA1. This gives us confidence that our Comprehensive Transformation Plan is on track and, when combined with our exciting innovation agenda, leaves the business well positioned for further progress in 2026.”

Management Transition

The Company announces that Susan O’Connor has completed her term as interim Chief Financial Officer, and Paul Murphy, Head of Group Reporting, has been promoted to the role of Interim Chief Financial Officer. The Company expresses its gratitude to Ms. O’Connor for her service and extends best wishes for her future endeavors.

Use of Non-IFRS Financial Measures

The Company’s unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentations of EBITDA and Adjusted EBITDA. The adjustments to the Company's IFRS results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends, and performance. Non-IFRS financial measures mainly exclude, if and when applicable, the effect of share-based compensation charges, depreciation, amortization and impairment charges.

EBITDA and Adjusted EBITDA is presented to evaluate the Company's financial and operating results on a consistent basis from period to period. The Company also believes that these measures, when viewed in combination with the Company's financial results prepared in accordance with IFRS, provides useful information to investors to evaluate ongoing operating results and trends. EBITDA and Adjusted EBITDA, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. EBITDA and Adjusted EBITDA are not measures of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company's operating profit/(loss) and EBITDA and Adjusted EBITDA are presented with the Company’s financial results available on the Company’s website, www.trinitybiotech.com/investor-relations/financial-reports .
[Source link]: https://www.globenewswire.com/news-release/2025/12/23/3209809/8624/en/Trinity-Biotech-Awarded-a-Major-Order-for-9-Million-TrinScreen-HIV-Tests.html


===== Company info for companies mentioned in news =====

Company name: can-fite biopharma
name: can-fite biopharma
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: engene
symbol: ENGN
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1766884746
name: engene
------------------------------------------------------------------

Company name: maia biotechnology
symbol: MAIA
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1766884747
name: maia biotechnology
------------------------------------------------------------------

Company name: trinity biotech
symbol: TRIB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1766884748
name: trinity biotech
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

